|
Mar 5
|
15 Highest Paying Jobs with a Psychology Degree
|
|
Mar 5
|
15 Countries with the Highest Prostate Cancer Rates in the World
|
|
Mar 5
|
13 Best Pharma Dividend Stocks To Buy in 2024
|
|
Mar 4
|
Here’s Why Aristotle Atlantic Core Equity Strategy Sold Bristol-Myers Squibb Company (BMY)
|
|
Jan 27
|
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
|
|
Jan 26
|
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
|
|
Jan 26
|
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
|
|
Jan 26
|
EMA recommends earlier use of Bristol Myers cell therapy for multiple myeloma
|
|
Jan 25
|
What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings
|
|
Jan 25
|
Is Bristol Myers Squibb Stock a Buy Now?
|
|
Jan 25
|
RayzeBio drew other pharma interest before Bristol Myers deal
|
|
Jan 24
|
10 Dividend Stocks with the Biggest Buyback Programs
|
|
Jan 23
|
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
|
|
Jan 23
|
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
|
|
Jan 23
|
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
|
|
Jan 23
|
UPDATE 2-US FDA requires 'boxed warning' for CAR-T cancer therapies
|
|
Jan 23
|
US FDA requires 'boxed warning' for CAR-T cancer therapies
|
|
Jan 22
|
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
|
|
Jan 22
|
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
|
|
Jan 22
|
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
|